NCT06724562View on ClinicalTrials.gov

This is an Observational Pre-post Study to Observe if the Off Label Use of Anti-IL1 Therapies, Such as Anakinra or Canakinumab, Can Block ACVR1-induced Flare Activity and Heterotopic Ossification in FOP

RecruitingOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
OTHER

Anti-IL1 Therapy

Anti-IL1 is a rescue therapy for FOP patients that is hypothesized to reduce flare activity and subsequent ossification in these patients

Trial Locations (1)

94143

RECRUITING

UCSF, San Francisco

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

University of California, San Francisco

OTHER